Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1-35. (Canceled)

36. (Currently Amended) A recombinant vector comprising a nucleotide sequence that encodes a truncated Flk-1, lacking a functional Flk-1 cytoplasmic domain but having a functional Flk-1 extracellular and transmembrane domain, which inhibits the cellular effects of VEGF binding.

37. (Previously Presented) The recombinant vector of claim 36 comprising a nucleotide sequence encoding amino acids 1 through 806 of Flk-1.

38. (Currently Amended) The recombinant vector of claim 36 in which the vector is a retrovirus vector, an adeno-associated viral vector or ~~and~~ a herpes viral vector.

39. (Previously Presented) The recombinant vector of claim 38 comprising a nucleotide sequence encoding amino acids 1 through 806 of Flk-1.

40. (Previously Presented) An engineered cell line that comprises the recombinant vector of claim 36 and expresses truncated Flk-1.

41. (Currently Amended) An engineered cell line that comprises the recombinant retrovirus vector of claim 38 or 39 ~~and produces infectious retrovirus particles encoding truncated Flk-1~~, wherein said cell line (i) produces infectious retrovirus particles encoding truncated Flk-1 and (ii) expresses truncated Flk-1 encoded by said retrovirus vector.

42. (Currently Amended) A recombinant truncated Flk-1 receptor protein, lacking a functional Flk-1 cytoplasmic domain but having a functional Flk-1 extracellular and transmembrane domain, wherein said protein inhibits the cellular effects of VEGF binding.

43. (Currently Amended) A method of inhibiting the cellular effects of VEGF in a mammal comprising administering to the mammal an effective amount of truncated Flk-1 receptor protein, lacking a functional Flk-1 cytoplasmic domain, which inhibits the cellular effects of VEGF binding.

44-46. (Canceled)

47. (Currently Amended) The recombinant truncated Flk-1 receptor protein of claim 42 comprising ~~a nucleotide sequence encoding~~ amino acids 1 through 806 of Flk-1.

48. (Currently Amended) The recombinant truncated Flk-1 receptor protein of claim 42 comprising ~~a nucleotide sequence encoding~~ amino acids 1 through 806 of Flk-1 but lacking the 561 COOH-terminal amino acids of the intracellular kinase domain of Flk-1.

49. (Previously Presented) The method of claim 43, wherein said truncated Flk-1 receptor protein has a functional Flk-1 extracellular and transmembrane domain.

50. (Previously Presented) The method of claim 49, wherein said truncated Flk-1 receptor protein comprises a nucleotide sequence encoding amino acids 1 through 806 of Flk-1.

51. (Previously Presented) The method of claim 49, wherein said truncated Flk-1 receptor protein comprises a nucleotide sequence encoding amino acids 1 through 806 of Flk-1 but lacking the 561 COOH-terminal amino acids of the intracellular kinase domain of Flk-1.

REMARKS

I. Introductory Remarks

Applicants respectfully request reconsideration of the present application in view of the foregoing amendments and following remarks. It is acknowledged that the foregoing amendments are submitted after final rejection. However, because the amendments do not